Literature DB >> 14623005

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.

Peter Schneider1, Stephen Hawser, Khalid Islam.   

Abstract

Iclaprim, a new selective dihydrofolate inhibitor was synthesized based on rational drug design. Iclaprim's interaction with a resistant Staphylococcus aureus dihydrofolate reductase (DHFR) is outlined in comparison to trimethoprim (TMP). This compound is active against methicillin, TMP and vancomycin resistant strains. Arpida Ltd. is developing Iclaprim for serious hospital infections from Gram-positive pathogens and respiratory tract infections.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14623005     DOI： 10.1016/j.bmcl.2003.07.023

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  33 in total

1.  Initial efforts toward the optimization of arylomycins for antibiotic activity.

Authors:  Tucker C Roberts; Mark A Schallenberger; Jian Liu; Peter A Smith; Floyd E Romesberg
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

2.  Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials.

Authors:  H Howard Xu; John D Trawick; Robert J Haselbeck; R Allyn Forsyth; Robert T Yamamoto; Rich Archer; Joe Patterson; Molly Allen; Jamie M Froelich; Ian Taylor; Danny Nakaji; Randy Maile; G C Kedar; Marshall Pilcher; Vickie Brown-Driver; Melissa McCarthy; Amy Files; David Robbins; Paula King; Susan Sillaots; Cheryl Malone; Carlos S Zamudio; Terry Roemer; Liangsu Wang; Philip J Youngman; Daniel Wall
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations.

Authors:  Peter A Smith; Tucker C Roberts; Floyd E Romesberg
Journal:  Chem Biol       Date:  2010-11-24

4.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

5.  In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.

Authors:  George G Zhanel; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

Review 6.  Antibacterial Antifolates: From Development through Resistance to the Next Generation.

Authors:  Alexavier Estrada; Dennis L Wright; Amy C Anderson
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

Review 7.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

8.  Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.

Authors:  José M Entenza; Andreas Haldimann; Marlyse Giddey; Sergio Lociuro; Stephen Hawser; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 9.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.